<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02177071</url>
  </required_header>
  <id_info>
    <org_study_id>GETAID 2014-03</org_study_id>
    <nct_id>NCT02177071</nct_id>
  </id_info>
  <brief_title>A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy</brief_title>
  <acronym>SPARE</acronym>
  <official_title>A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Saint-Louis Hospital, Paris, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase IV&#xD;
&#xD;
      Design : Prospective, open-label, randomized three-arms study&#xD;
&#xD;
      Main Inclusion criteria Luminal Crohn's disease patients with steroid free remission for at&#xD;
      least 6 months and a combination therapy with infliximab and anti-metabolites for at least 8&#xD;
      months&#xD;
&#xD;
      Primary objective To demonstrate that Infliximab scheduled maintenance with or without&#xD;
      antimetabolites is superior to antimetabolites alone to maintain sustained steroid-free&#xD;
      remission over 2 years, while the latter is non inferior with regards to the mean time spent&#xD;
      in remission over the same duration&#xD;
&#xD;
      Main co-primary end points Clinical relapse rate at 2 years Mean remission duration within 2&#xD;
      years Study treatment Infliximab, Mercaptopurine, azathioprine, methotrexate.&#xD;
&#xD;
      Number of subjects 225 randomized patients (75 per arm)&#xD;
&#xD;
      Study duration: 3 + 2 years Enrollment: 3 years Follow-up: 2 years&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      3. STUDY OBJECTIVES 3.1. Primary objective To assess the effect of two withdrawal strategies&#xD;
      over two years in patients with stable remission for more than 6 months on combination&#xD;
      therapy with infliximab and antimetabolites, and demonstrate that continued combination of&#xD;
      infliximab and antimetabolites or continued monotherapy with infliximab are both superior to&#xD;
      antimetabolites alone for maintaining sustained steroid-free clinical remission, while&#xD;
      antimetabolites alone are non-inferior with regards to the mean time spent in remission 3.2.&#xD;
      Secondary objectives&#xD;
&#xD;
        -  To identify baseline predictive factors of relapse in the three study groups.&#xD;
&#xD;
        -  To assess the ability of blood CRP and fecal calprotectin to predict short term relapse&#xD;
           in the three groups.&#xD;
&#xD;
        -  To assess time spent inclinical remission in the three groups.&#xD;
&#xD;
        -  To assess the rate of treatment failure in the three study groups.&#xD;
&#xD;
        -  To assess the time to treatment failure in the three study groups.&#xD;
&#xD;
        -  To assess progression of bowel damage in the three groups.&#xD;
&#xD;
        -  To assess the safety and efficacy of infliximab retreatment in the antimetabolites&#xD;
           group.&#xD;
&#xD;
        -  To assess safety in the three study groups.&#xD;
&#xD;
        -  To assess the health related quality of life in the three study groups.&#xD;
&#xD;
        -  To assess direct and indirect costs in the three study groups.&#xD;
&#xD;
        -  To assess evolution of blood CRP and fecal calprotectin in the three study groups.&#xD;
&#xD;
        -  To assess evolution of infliximab trough levels and ATI in the two infliximab scheduled&#xD;
           maintenance groups.&#xD;
&#xD;
        -  To assess genetic association with the various clinical and biological outcomes.&#xD;
&#xD;
        -  To assess the impact of 6TGN levels on the various clinical and biological outcomes in&#xD;
           the purine treated patients 4. STUDY POPULATION 4.1. Selection of study population&#xD;
           Patients to be included are those who have been in steroid free remission for at least 6&#xD;
           months and with scheduled infliximab/antimetabolites combination therapy for at least 8&#xD;
           months, with a scheduled infliximab treatment administrated every 8 weeks for the last 4&#xD;
           months.&#xD;
&#xD;
      4.2. Source of recruitment Patients are recruited from participating GETAID IBD-centers in&#xD;
      France, Belgium and SOIBD IBD-centers in Sweden, and selected centres in UK, Germany,&#xD;
      Netherland and Australia 4.3. Inclusion criteria&#xD;
&#xD;
      To be eligible all of the following criteria must be met:&#xD;
&#xD;
        -  Diagnosis of Crohn's disease.&#xD;
&#xD;
        -  Male or female, age &gt; 18 years.&#xD;
&#xD;
        -  Currently treated with a combination therapy with infliximab and anti-metabolites for&#xD;
           luminal Crohn's disease.&#xD;
&#xD;
        -  Combined therapy with scheduled infliximab and anti-metabolites for at least 8 months.&#xD;
&#xD;
        -  Scheduled administration of infliximab 5 mg/Kg every 8 weeks over the last 4 months.&#xD;
&#xD;
        -  Antimetabolites administered at a stable dosage for the last 3 months: at least 1 mg/Kg&#xD;
           or 2 mg/Kg for mercaptopurine and azathioprine, respectively, or the highest tolerated&#xD;
           dosage if intolerance to standard dose;(lower dose than standard dose is also allowed if&#xD;
           6 TGN &gt; 235 pmol) ; at least 15 mg/week subcutaneously for methotrexate.&#xD;
&#xD;
        -  Patients in steroid free clinical remission for at least 6 months according to&#xD;
           retrospective assessment of the patients' files.&#xD;
&#xD;
        -  CDAI &lt; 150 at baseline.&#xD;
&#xD;
        -  A contraceptive during the whole study&#xD;
&#xD;
        -  Patients able to understand the information provided to them and to give written&#xD;
           informed consent for the study&#xD;
&#xD;
      4.4. Exclusion criteria&#xD;
&#xD;
        -  Patients who have presented a severe acute or delayed reaction to infliximab.&#xD;
&#xD;
        -  Perianal fistulae as the main indication for infliximab treatment&#xD;
&#xD;
        -  Active perianal/abdominal fistulae at time of inclusion, defined by active drainage&#xD;
&#xD;
        -  Patients with ostomy or ileoanal pouch&#xD;
&#xD;
        -  Pregnancy or planned pregnancy during the study&#xD;
&#xD;
        -  Inability to follow study procedures as judged by the investigator&#xD;
&#xD;
        -  Non-compliant subjects.&#xD;
&#xD;
        -  Participation in another therapeutic study&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 9, 2015</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Actual">June 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>co-primary efficacy end points</measure>
    <time_frame>2 ans</time_frame>
    <description>There will be two co-primary efficacy end points&#xD;
Relapse rate at 2 years, relapse being defined by either one of the following events:&#xD;
A CDAI&gt;250 at any visit or between 150 and 250 with an increase of at least 70 points, over two consecutive visits one week apart associated with a CRP &gt; 5 mg/l or a fecal calprotectin &gt; 250 microg/g&#xD;
A new opening fistula, perianal or entero-cutaneous.&#xD;
An intra-abdominal abcess (size of at least 3 cm) or perianal abcess (size of at least 2 cm)&#xD;
An episode of intestinal obstruction due to Crohn's lesions confirmed by medical imaging and requiring hospitalisation (also considered as treatment failure, see below)&#xD;
Mean restricted time spent in remission This time will be computed in all patients, from baseline (CDAI &lt;150 and with absence of fistula drainage) until relapse, as defined above, within the 2 first years. First and subsequent remissions will be summed up within the two first years.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>relapse in each arm.</measure>
    <time_frame>2 years</time_frame>
    <description>Time to relapse in each arm.&#xD;
Factors associated with time to relapse.&#xD;
Time to relapse according to CRP and calprotectin value measured every 2 months over the follow up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained clinical remission</measure>
    <time_frame>2years</time_frame>
    <description>Sustained clinical remission defined by CDAI&lt;150 without steroids over two years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment failure</measure>
    <time_frame>2 years</time_frame>
    <description>Treatment failure rate. Treatment failure is defined by not achieving remission after treatment adaptation following a relapse according to protocol (CDAI&lt;150 or, in case of relapse defined by the occurence of a new fistula, the absence of fistula closure). The occurence of an intra-abdominal or peri-anal abcess and the occurence of an intestinal obstruction due to Crohn's lesions and requiring a surgical resection or an endoscopic dilatation are also directly considered as treatment failure and will not be managed by treatment adaptation according to protocol.&#xD;
Time to treatment failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tissue damage progression</measure>
    <time_frame>2 years</time_frame>
    <description>- Tissue damage progression will be assessed by the Lémann Score absolute and relative change between baseline and en of the study (2 years).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoscopic remission</measure>
    <time_frame>2 years</time_frame>
    <description>Endoscopic remission at the end of study</description>
  </secondary_outcome>
  <other_outcome>
    <measure>disability index</measure>
    <time_frame>2 YEARS</time_frame>
    <description>disability index</description>
  </other_outcome>
  <other_outcome>
    <measure>adverse events and SAE</measure>
    <time_frame>2 YEARS</time_frame>
    <description>adverse events and SAE, events related to re-infusions,</description>
  </other_outcome>
  <other_outcome>
    <measure>BIOLOGICS</measure>
    <time_frame>2 YEARS</time_frame>
    <description>trough levels of infliximab, ATI , hsCRP, fecal calprotectin</description>
  </other_outcome>
  <other_outcome>
    <measure>SCORES AND COST</measure>
    <time_frame>2 YEARS</time_frame>
    <description>direct medical costs, work productivity and activity index, short IBDQ</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">211</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>INFLIXIMAB AND ANTI METABOLITE</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>continuing scheduled infliximab treatment and anti-metabolite</description>
  </arm_group>
  <arm_group>
    <arm_group_label>STOP INFLIXIMAB CONTINUING ANTI METABOLITE</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>discontinuing infliximab and continuing the anti-metabolite</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CONTINUING INFLIXIMAB AND discontinuing anti-metabolites</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>CONTINUING INFLIXIMAB AND DISCONTINUING ANTI METABOLITE</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INFLIXIMAB</intervention_name>
    <arm_group_label>STOP INFLIXIMAB CONTINUING ANTI METABOLITE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZATHIOPRINE</intervention_name>
    <arm_group_label>CONTINUING INFLIXIMAB AND discontinuing anti-metabolites</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MERCAPTOPURINE</intervention_name>
    <arm_group_label>CONTINUING INFLIXIMAB AND discontinuing anti-metabolites</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <arm_group_label>CONTINUING INFLIXIMAB AND discontinuing anti-metabolites</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Crohn's disease.&#xD;
&#xD;
          -  Male or female, age &gt; 18 years.&#xD;
&#xD;
          -  Currently treated with a combination therapy with infliximab and anti-metabolites for&#xD;
             luminal Crohn's disease.&#xD;
&#xD;
          -  Combined therapy with scheduled infliximab and anti-metabolites for at least 8 months.&#xD;
&#xD;
          -  Scheduled administration of infliximab 5 mg/Kg every 8 weeks over the last 4 months.&#xD;
&#xD;
          -  Antimetabolites administered at a stable dosage for the last 3 months: at least 1&#xD;
             mg/Kg or 2 mg/Kg for mercaptopurine and azathioprine, respectively, or the highest&#xD;
             tolerated dosage if intolerance to standard dose; at least 15 mg/week subcutaneously&#xD;
             for methotrexate.&#xD;
&#xD;
          -  Patients in steroid free clinical remission for at least 6 months according to&#xD;
             retrospective assessment of the patients' files.&#xD;
&#xD;
          -  CDAI &lt; 150 at baseline.&#xD;
&#xD;
          -  A contraceptive during the whole study for childbearing potential female patients.&#xD;
&#xD;
          -  Patients able to understand the information provided to them and to give written&#xD;
             informed consent for the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have presented a severe acute or delayed reaction to infliximab.&#xD;
&#xD;
          -  Perianal fistulae as the main indication for infliximab treatment&#xD;
&#xD;
          -  Active perianal/abdominal fistulae at time of inclusion, defined by active drainage&#xD;
&#xD;
          -  Patients with ostomy or ileoanal pouch&#xD;
&#xD;
          -  Pregnancy or planned pregnancy during the study&#xD;
&#xD;
          -  Inability to follow study procedures as judged by the investigator&#xD;
&#xD;
          -  Non-compliant subjects.&#xD;
&#xD;
          -  Participation in another therapeutic study&#xD;
&#xD;
          -  Steroid use ≤6 months prior to screening&#xD;
&#xD;
          -  Currently receiving steroids, immunosuppressive agents (other than purine,&#xD;
             methotrexate), biologic treatment (other than infliximab) or thalidomide&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Laharie</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St Vincent Hospital</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU LIEGE - Sart Tilman</name>
      <address>
        <city>Liege</city>
        <state>Province De Liège</state>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gent University Hospital</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Clermont-Ferrand</name>
      <address>
        <city>Clermont-ferrand</city>
        <state>Auvergne Rhone Alpes</state>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU LYON</name>
      <address>
        <city>Pierre Benite</city>
        <state>Auvergne Rhone Alpes</state>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Saint Etienne</name>
      <address>
        <city>St Etienne</city>
        <state>Auvergne Rhone Alpes</state>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Besancon</name>
      <address>
        <city>Besancon</city>
        <state>Bourgogne-Franche-Comte</state>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Rennes</name>
      <address>
        <city>Rennes</city>
        <state>Bretagne</state>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Tours</name>
      <address>
        <city>Tours</city>
        <state>Centre Val De Loire</state>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Reims</name>
      <address>
        <city>Reims</city>
        <state>Grand Est</state>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Nancy</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <state>Grand Est</state>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Amiens</name>
      <address>
        <city>Amiens</city>
        <state>Hauts De France</state>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Lille</name>
      <address>
        <city>Lille</city>
        <state>Hauts De France</state>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chr Valencienne</name>
      <address>
        <city>Valenciennes</city>
        <state>Hauts De France</state>
        <zip>59300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Beaujon</name>
      <address>
        <city>Clichy</city>
        <state>Ile De France</state>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Bicetre</name>
      <address>
        <city>Le Kremlin Bicetre</city>
        <state>Ile De France</state>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Kremlin Bicetre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <state>Ile De France</state>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Louis</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital St Antoine</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montsouris Mutualist Institute</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <zip>75674</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Caen Unversity Hospital</name>
      <address>
        <city>Caen</city>
        <state>Normandie</state>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux - Pessac</name>
      <address>
        <city>Pessac</city>
        <state>Nouvelle-aquitaine</state>
        <zip>33700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Montpellier</name>
      <address>
        <city>Montpellier</city>
        <state>Occitanie</state>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Toulouse</name>
      <address>
        <city>Toulouse</city>
        <state>Occitanie</state>
        <zip>31403</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Nantes</name>
      <address>
        <city>Nantes</city>
        <state>Pays De La Loire</state>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU NICE</name>
      <address>
        <city>Nice</city>
        <state>Provences Alpes Cote d'Azur</state>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Joseph</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>June 26, 2014</study_first_submitted>
  <study_first_submitted_qc>June 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2014</study_first_posted>
  <last_update_submitted>July 6, 2021</last_update_submitted>
  <last_update_submitted_qc>July 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CROHN DISEASE</keyword>
  <keyword>INFLIXIMAB</keyword>
  <keyword>COMBINATION THERAPY</keyword>
  <keyword>steroid free remission</keyword>
  <keyword>anti-metabolites</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Mercaptopurine</mesh_term>
    <mesh_term>Azathioprine</mesh_term>
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

